Challenges and opportunities in microRNA-based cancer therapeutics
Jingfang Ju
Abstract
The 2024 Nobel Prize honored groundbreaking microRNA (miRNA) discoveries that unveiled the critical functions of miRNAs in fundamental biology and human health. Despite promising therapeutic potential, there are no Food and Drug Administration (FDA)-approved miRNA-based cancer therapies. This commentary discusses the progress and challenges of miRNA-based cancer therapeutics and their potential impact on future clinical oncology. The 2024 Nobel Prize honored groundbreaking microRNA (miRNA) discoveries that unveiled the critical functions of miRNAs in fundamental biology and human health. Despite promising therapeutic potential, there are no Food and Drug Administration (FDA)-approved miRNA-based cancer therapies. This commentary discusses the progress and challenges of miRNA-based cancer therapeutics and their potential impact on future clinical oncology.